Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
| ▸ | CEL | P19835 | 2/20 | 0.32 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2996217 | 0.96 | SIGMAR1 (0.45) | CYP1A2SIGMAR1CYP2D6OPRK1CEL | |
| SCHEMBL10748317 | 0.88 | CYP1A2 (0.38) | CYP1A2SIGMAR1CYP2D6 | |
| SCHEMBL28339122 | 0.78 | CYP1A2 (0.50) | CYP1A2SIGMAR1CYP2D6 | |
| SCHEMBL2688034 | 0.78 | CYP1A2 (0.45) | CYP1A2CYP2D6 | |
| SCHEMBL8080519 | 0.78 | CYP1A2 (0.65) | CYP1A2SIGMAR1CELSLC18A3EPHX1 | |
| SCHEMBL8852810 | 0.77 | CYP1A2 (0.39) | CYP1A2CYP2D6 | |
| SCHEMBL30342933 | 0.76 | CYP1A2 (0.42) | CYP1A2SIGMAR1CYP2D6EPHX1 | |
| SCHEMBL29336691 | 0.76 | SIGMAR1 (0.50) | CYP1A2SIGMAR1CYP2D6 | |
| SCHEMBL4969658 | 0.75 | CYP1A2 (0.68) | CYP1A2SIGMAR1CELSLC18A3EPHX1 | |
| SCHEMBL10579794 | 0.75 | CYP1A2 (0.68) | CYP1A2SIGMAR1CELSLC18A3EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6753409-B1 | FOR TREATMENT OF MYOCARDIAL INFARCTION, STROKE, PERIPHERAL ARTERIAL DISEASE AND DISSEMINATED INTRAVASCULAR COAGULATION | AVENTIS PHARMACEUTICALS INC. | 2004-06-22 | — | — | US | disclosed |
| US-20020002268-A1 | Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides | AVENTIS PHARMACEUTICALS INC. | 2002-01-03 | — | — | US | disclosed |
| EP-0929572-A4 | ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES | AVENTIS PHARM PROD INC (US) | 2001-09-12 | — | — | EP | disclosed |
| US-6274705-B1 | INHIBIT PLATELET AGGREGATION AND THROMBUS FORMATION, USEFUL IN PREVENTION AND TREATMENT OF THROMBOSIS | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2001-08-14 | — | — | US | disclosed |
| EP-0812205-B1 | ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES | RHONE POULENC RORER PHARMA (US) | 2001-03-14 | — | — | EP | disclosed |
| EP-0923553-A4 | STABLE NON-HYGROSCOPIC CRYSTALLINE FORM OF N- N-N-(4-(PIPERIDIN-4-YL)BUTANOYL)-N-ETHYLGLYCYL] COMPOUNDS | RHONE POULENC RORER PHARMA (US) | 1999-12-08 | — | — | EP | disclosed |
| EP-0929572-A1 | ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-07-21 | — | — | EP | disclosed |
| EP-0923553-A1 | STABLE NON-HYGROSCOPIC CRYSTALLINE FORM OF N- N-N-(4-(PIPERIDIN-4-YL)BUTANOYL)-N-ETHYLGLYCYL] COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-06-23 | — | — | EP | disclosed |
| US-5866685-A | Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1999-02-02 | — | — | US | disclosed |
| US-5780590-A | Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-07-14 | — | — | US | disclosed |
| WO-1998017678-A1 | ANTITHROMBOTIC AZACYCLOALKYLALKANOYL PEPTIDES AND PSEUDOPEPTIDES | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-04-30 | — | — | WO | disclosed |
| WO-1998007696-A1 | STABLE NON-HYGROSCOPIC CRYSTALLINE FORM OF N-[N-N-(4-(PIPERIDIN-4-YL)BUTANOYL)-N-ETHYLGLYCYL] COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002268-A1 | Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides | PLAT, SELP, PIGS | CYP1A2 4294/4885SIGMAR1 4705/4885CYP2D6 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.